Successful treatment of refractory pure red cell aplasia with eltrombopag after ABO-incompatible allogeneic hematopoietic stem cell transplantation

摘要

Pure red cell aplasia(PRCA) is a well-recognized complication of ABO major mismatched allogeneic hematopoietic stem cell transplantation(allo-HSCT), with a reported incidence of 10% – 20%(Zhidong et al., 2012;Busca et al., 2018). It is clinically characterized by anemia, reticulocytopenia,and the absence of erythroblasts in a normal-appearing bone marrow biopsy(Shahan and Hildebrandt, 2015).The mechanism for PRCA has been presumed to be persistence of recipient isoagglutinins, produced by residual host B lymphocytes or plasma cells。